Why AbbVie Could Join the M&A Mania Soon Post author:Sam Post published:January 30, 2018 Post category:BioPharma The company expects to only pay a tax rate of 9 percent this year, which will free up a lot of cash. Source: BioSpace You Might Also Like GRAIL Poaches New CEO From Roche, Genentech December 13, 2017 argenx Bags $231M in Upsized U.S. IPO December 13, 2017 This is the Drug That Could Kick Regeneron's Stock Into Gear December 13, 2017